Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Devices & Dosimetry

Fading the spots: a pilot case series of partial unilateral lentiginosis treated with Q-switched Nd: YAG laser

Q-switched Nd:YAG laser represents a safe, effective, and reproducible therapeutic option for PUL, offering substantial pigment clearance and meaningful improvement in patient quality of life.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors treated six patients with partial unilateral lentiginosis using a Q-switched Nd:YAG laser at 532 nm, with sessions every 2 to 3 weeks. They report that five patients improved by more than 70% and one cleared completely, with high patient satisfaction and only mild side effects. The study was a small, descriptive pilot case series without a control group.

Participants
6
Who or what was studied
Six patients (four females, two males) aged 10 to 32 years with partial unilateral lentiginosis
Wavelengths
532 nm
Limits stated in the abstract
Small descriptive pilot case series with six patients and no control group or inferential statistics.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Introduction

Partial unilateral lentiginosis (PUL) is rare pigmentary disorder characterized by clusters of unilateral lentiginous macules that can cause significant cosmetic and psychosocial distress. Despite its benign nature, there is no established standard treatment, and existing options often yield inconsistent results. This pilot case series evaluated the efficacy and safety of the Q-switched Nd:YAG laser (532 nm) in patients with PUL. About the Case Series. ABOUT THE CASE SERIES: Six patients (four females, two males; age range 10-32 years) underwent treatment with Q-switched Nd:YAG laser using the 532 nm wavelength. Given the rarity of the condition, this exploratory study was designed to descriptively evaluate clinical and dermoscopic outcomes rather than perform inferential statistical analysis. Treatment was initiated at low fluences and gradually titrated to a maximum of 2.5 J/cm² and 200 mJ, with sessions performed at 2-3 week intervals (mean of 23 sessions). Outcomes were assessed clinically, dermoscopically, and through patient-reported satisfaction, and were independently reviewed by three dermatologists. One patient achieved complete clearance, while the remaining five showed more than 70% improvement, with a mean dermoscopic pigment score reduction of approximately 68.6%. Patient satisfaction was high (mean VAS 8.8/10), with particular improvement noted in self-confidence and social interactions. Adverse effects were mild and included transient erythema and pigmentary changes, none of which required discontinuation.

Conclusion

Q-switched Nd:YAG laser represents a safe, effective, and reproducible therapeutic option for PUL, offering substantial pigment clearance and meaningful improvement in patient quality of life.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
532 nm

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Laser, Visual analogue scale, Wavelength, Fluence. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies